RIG-I helicase domain (human, re

Confirm delete?

RIG-I helicase domain (human, recombinant)

Zoom

Cat No: 25620

Proteins - More Proteins

Retinoic acid-inducible gene I (RIG-I), also known as DDX58, is a cytosolic DExD/H-box RNA helicase and an immune sensing receptor encoded by DDX58 in humans.{48287} It is composed of a C-terminal repressor domain, a central RNA helicase domain, and t...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

RIGI C 268 F 268F C268 DDX 58 Hbox NF?B IFN? RIG-1 RIG1 WB

Product Overview:
Retinoic acid-inducible gene I (RIG-I), also known as DDX58, is a cytosolic DExD/H-box RNA helicase and an immune sensing receptor encoded by DDX58 in humans.{48287} It is composed of a C-terminal repressor domain, a central RNA helicase domain, and two N-terminal caspase recruitment domains (CARDs).{48287,48288} Following recognition of viral dsRNA by the C-terminal and helicase domains, the helicase domain induces an ATP-dependent conformational change, allowing for interaction of the CARD domains with mitochondrial antiviral-signaling protein (MAVS) and induction of a type I interferon (IFN) response.{48287,48288,48289} A single amino acid substitution of phenylalanine for cysteine at position 268 in the RIG-I helicase domain (RIG-IC268F) leads to enhanced NF-κB activity and expression of IFN-β in basal and poly (I:C)-stimulated cells.{48290} Overexpression of RIG-IC268F in human trabecular meshwork (HTM) cells induces cell death and is positively correlated with glaucoma, a core symptom in the type I interferonopathy atypical Singleton-Merten syndrome.

Size	50 µg
Shipping	dry ice
Formulation	50 mM HEPES, pH 8.0, with 150 mM sodium chloride and 10% glycerol
Purity	≥80% estimated by SDS-PAGE
Custom Code	3504.00
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.